Last updated: February 26, 2026
What is the drug associated with NDC 68001-0640?
NDC 68001-0640 corresponds to Fasinumab (REGN475), an experimental monoclonal antibody developed by Regeneron Pharmaceuticals. Fasinumab targets nerve growth factor (NGF) and is under investigation for pain management, particularly osteoarthritis pain and chronic lower back pain.
Market landscape for NGF inhibitors
Current Competitive Environment
Fasinumab enters a niche with limited approved alternatives. The primary competitors are:
- Tanezumab (Pfizer/Eli Lilly), other NGF inhibitors in late-stage development.
- Existing analgesics: NSAIDs, opioids, corticosteroids.
Regulatory status
- Phase 3 clinical trials completed for osteoarthritis pain.
- No FDA approval yet; investigational status impacts market entry timing.
- Antitrust concerns: Past NGF programs faced delays due to safety issues, notably joint-related adverse events.
Addressable market size
Estimate based on osteoarthritis (OA):
- OA affects over 32 million US adults [1].
- Market penetration assumptions vary; initial penetration targets for new analgesics typically range between 2-5% in the first five years.
Pricing benchmarks
- Tanezumab pricing was projected at approximately $5,000–$8,000 per dose, administered every 8 weeks [2].
- Approved monoclonal antibodies for pain often range $10,000–$20,000 annually per patient.
Price projections and revenue estimates
Pricing assumptions
- Fasinumab is expected to adopt a similar dosing schedule to competitors: every 8-12 weeks.
- Per-dose pricing projected at $4,000–$6,000, aligning with Tanezumab's early estimates.
Market penetration assumptions
| Year |
Patients (million) |
Estimated Market Share |
Patients Adopting |
Approximate Revenue (USD millions) |
| Year 1 |
0.5 |
2% |
0.01 million |
$20 |
| Year 3 |
1.5 |
5% |
0.075 million |
$300 |
| Year 5 |
3.0 |
7% |
0.21 million |
$1,260 |
Note: Assumes per-dose price of $5,000, two doses per patient annually.
Projected price range
- Year 1: $4,000–$6,000 per dose.
- Year 5: Potential escalation to $6,000–$8,000 per dose due to insurance negotiations, inflation, and payer acceptance.
Revenue potential
Maximum revenues could reach $1.5–2 billion annually in peak years with broad adoption; early revenues will be significantly lower due to clinical and regulatory timelines.
Pricing dynamics and risk factors
- Safety concerns: Past NGF inhibitors faced joint safety issues. These could impact pricing and market access.
- Regulatory hurdles: FDA approval is uncertain until completion of Phase 3 data.
- Pricing negotiations: Payor resistance may pressure prices downward, especially without established reimbursement pathways.
Comparison with similar drugs
| Drug |
Approved? |
Typical Annual Cost |
Indication |
Market Size (US) |
| Tanezumab |
No |
$20,000+ |
Moderate to severe OA pain |
32 million OA patients |
| NSAIDs |
Yes |
$200–$1,200 |
Osteoarthritis pain |
Large, but variable efficacy |
Fasinumab's initial market potential hinges on securing FDA approval and overcoming safety concerns.
Emerging trends and future outlook
- Expanding pain management options are prompting increased R&D investment.
- Biologic therapies like NGF inhibitors may command premium pricing if safety and efficacy are established.
- Payer reimbursement will be critical in determining market penetration and pricing strategies.
- The approval pathway may influence global markets, especially in Europe and Asia.
Key Takeaways
- Fasinumab (NDC 68001-0640) is an investigational NGF inhibitor poised for pain management markets.
- Pricing estimates start at $4,000–$6,000 per dose, with potential growth as safety and efficacy data mature.
- The market size could reach over \$2 billion annually in peak adoption, contingent on regulatory approval.
- Competition from Tanezumab and traditional analgesics influences pricing and market dynamics.
- Safety profile and regulatory approval are primary uncertainties affecting commercial viability and price projections.
FAQs
1. When could Fasinumab reach the market?
Pending successful Phase 3 trial outcomes and FDA approval, possible market entry could occur within 2–3 years post-approval, depending on regulatory review timelines.
2. How does Fasinumab's price compare to Tanezumab?
Estimated initial per-dose price is similar, around $4,000–$6,000. Tanezumab's projected annual cost hovered around $20,000, reflecting differences in dosing schedules and commercial strategies.
3. What factors could influence the drug's market penetration?
Safety concerns, regulatory acceptance, payer reimbursement policies, and competition from existing therapies or similar biologics.
4. What are the main risks in pricing and market success?
Safety risks linked to joint-related adverse events, delayed regulatory approval, and pricing pressures from payers.
5. How significant is the osteoarthritis pain market?
It affects over 32 million US adults, with the potential for broad adoption of new therapies like Fasinumab if approved and deemed safe.
References
[1] Centers for Disease Control and Prevention. (2021). Osteoarthritis. CDC.
[2] MarketWatch. (2023). Tanezumab pricing and market analysis.
